BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN-PROTEIN INTERACTION YAP/TAZ-TEAD Russian patent published in 2024 - IPC C07D307/81 C07D401/14 C07D403/04 C07D405/04 C07D405/10 C07D405/12 C07D405/14 C07D407/12 C07D413/04 C07D417/04 C07D491/04 A61K31/343 A61K31/443 A61P35/00 

FIELD: pharmaceutics.

SUBSTANCE: invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof,

where X is selected from CH; and N; A is phenyl; R_w is selected from (i) hydrogen; and (ii) C₁-C₃ alkyl; Q is selected from (i) -C(R⁷)₂-NH-R₁; and (ii) 4-, 5- or 6-membered saturated heterocyclic ring containing one or two heteroatoms independently selected from N and O, provided that at least one N heteroatom is present and it is in the α-position with respect to the carbon atom binding Q to the rest of the molecule, where the heterocyclic ring is unsubstituted or substituted with one or more substituents independently selected from hydroxy, C₁-C₃alkyl and halogen; R₁ is selected from (i) C₁-C₆alkyl and (ii) R_1a; where R_1a is C₃-C₆cycloalkyl, optionally independently substituted once or more than once with hydroxy, C₁-C₆alkyl or halogen; R₂ is halogen; R₃ is halogen; R₄ is halogen; R₅ is selected from C₁-C₆alkoxy and hydroxyC₁-C₆alkoxy; R₆ is C(O)NHR^6a; R^6a is selected from (i) hydrogen and (ii) C₁-C₃alkyl; and each R⁷ is hydrogen, as well as pharmaceutical compositions based thereon.

EFFECT: obtaining novel compounds which have YAP/TAZ-TEAD protein-protein interaction (PPI) inhibitory activity and can be used to treat diseases mediated by said activity, for example, cancer or tumor.

18 cl, 176 ex, 2 tbl